Bone/Mineral Metabolism News

The Healio and Endocrine Today Editors have compiled a list of the top endocrinology news stories from 2022.

The FDA has approved abaloparatide, a parathyroid hormone-related peptide analog, to increase bone mineral density among men with osteoporosis at high risk for fracture, according to an industry press release.

A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or denosumab in addition to adequate hydration for adults with moderate hypercalcemia of malignancy.

Subclinical hyperthyroidism is an independent risk factor associated with fracture among white and Black middle-aged adults, according to results from a community-based cohort study published in JAMA Network Open.

A belt device that mechanically stimulates bones through vibration slowed the decline in bone strength among adults with osteopenia, according to top-line results announced in an industry press release.

During the past 20 years, Endocrine Today has covered the latest advancements surrounding osteoporosis care. For its 20th year, the publication is taking a look back.

SAN DIEGO — Weight loss through caloric restriction can improve cardiometabolic risk, chronic conditions and physical function for older adults with obesity, but certain factors should be considered when designing an intervention.

CHICAGO — Implementation of an endocrinology fast-track program may allow patients with poorly controlled diabetes to successfully obtain acceptable blood sugar control prior to spine surgery, according to results presented here.

In a post from April about my struggle with osteoporosis, I wrote about my own case of the disease, which was unique in many ways.

About 30% of a cohort of gender-diverse youths had low whole-body bone mineral density z scores prior to initiation of puberty blockers or gender-affirming hormones, according to findings published in Transgender Health.